Browse drugs

… therapy will potentially improve patient outcomes and decrease SABA over-reliance. Prioritising DPIs or soft mist inhalers when cli…

…acting β2-agonists (LABAs), long-acting muscarinic antagonists (LAMAs) and triple therapy (ICS/LABA/LAMA), on exacerbation rates and …

…03 to 2.21). There were no frequent serious adverse events. The intravenous magnesium sulphate group had a lower hospitalisation rate (RR=1.52, 95% CI 1.26 to…

…atients started the deprescribing pathway. So far, 100% (n= 11) theophylline, 98% (n= 45) montelukast, 82% (n= 49) LAMA inhalers, 85% (n= 13…

…e pMDIs. The most common class of inhaler device collected were SABA (1,127), ICS/LABA (474), and ICS/LABA/LAMA inhalers (445). The …

…als from primary care. From 602, 41% had been prescribed >three SABA inhalers in the past year, with 35% being under 8-years-old. In…

…er of respiratory medications; a higher proportion received any ICS (89% vs 74%), ICS+LABA (47% vs 14%), and SABA (99.5% vs 91.4%).…

…from approaches utilising separate ICS-containing preventer and SABA reliever inhalers. SENTINEL is a quality improvement framework …

…2 emissions B) Healthcare-related emissions C) Emissions due to SABA inhalers D) Emissions due to non-SABA medications in the period…

…SD – standard deviation, GLI - Global Lung Function Initiative, SABA – Short-acting beta 2-agonists, ICS – inhaled corticosteroids, …